China NMPA Clears Five Novel Drugs and Two New Indications in September Approval Wave
China’s National Medical Products Administration (NMPA) delivered another busy round of regulatory decisions in early September 2026, clearing a group of innovative therapies spanning oncology, infectious disease, cardiovascular medicine, hematology and…
China’s NMPA Conditionally Approves GenrixBio’s Velinotamig for Heavily Pretreated Multiple Myeloma
China’s National Medical Products Administration (NMPA) has granted conditional approval to velinotamig (GR1803), a BCMA×CD3 bispecific antibody developed by Genrix Bio and partnered with Fosun Pharma’s YaoPharma, for adults with heavily pretreated…